BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 04, 2013
 |  BC Week In Review  |  Company News  |  Deals

Idenix, Medivir, J&J deal

The companies partnered to develop an all oral, interferon-free HCV combination therapy. The partners will evaluate through Phase II testing combinations of Idenix's IDX719, an HCV NS5A protein inhibitor; Johnson & Johnson's TMC647055, a non-nucleoside HCV NS5B polymerase inhibitor; and simeprevir ( TMC435), an...

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >